Rallybio Corporation Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Rallybio Corporation (Nasdaq: RLYB) has successfully closed its initial public offering (IPO) of 7,130,000 shares at $13.00 each, raising approximately $92.7 million in gross proceeds. This includes the full exercise of underwriters' option for an additional 930,000 shares. The offering's registration statement became effective on July 28, 2021, with Jefferies, Cowen, and Evercore ISI as joint book-running managers. Rallybio focuses on developing therapies for severe and rare diseases and aims to advance its product portfolio, which targets various rare disease areas.
- Raised approximately $92.7 million in gross proceeds from the IPO.
- Enhanced capacity to develop therapies for severe and rare diseases.
- None.
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced the closing of its initial public offering of 7,130,000 shares of common stock, including the exercise in full by the underwriters of their option to purchase up to 930,000 additional shares of common stock, at a public offering price of
The aggregate gross proceeds to Rallybio from the offering were approximately
Jefferies, Cowen and Evercore ISI are acting as joint book-running managers for the offering.
A registration statement relating to the offering of these securities was filed with the U.S. Securities and Exchange Commission and became effective on July 28, 2021. The offering was made only by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at (877) 821-7388, or by email at prospectus_department@Jefferies.com; Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY, 11717, Attention: Prospectus Department, or by e-mail at PostSaleManualRequests@broadridge.com; and Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, New York 10055, or by telephone at (888) 474-0200, or by email at ecm.prospectus@evercore.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Rallybio
Rallybio is a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases. Since its launch in January 2018, Rallybio has built a portfolio of promising product candidates, which are now in development to address rare diseases in the areas of hematology, immuno-inflammation, maternal fetal health, and metabolic disorders. The Company’s mission is being advanced by a team of highly experienced biopharma industry leaders with extensive research, development, and rare disease expertise. Rallybio is headquartered in New Haven, Connecticut, with an additional facility at the University of Connecticut’s Technology Incubation Program in Farmington, Connecticut. For more information, please visit www.rallybio.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210802005461/en/
FAQ
What was the initial public offering price for Rallybio shares?
How many shares were included in the Rallybio IPO?
Who managed Rallybio's initial public offering?
What were the total gross proceeds from Rallybio's IPO?
When did the registration statement for Rallybio's IPO become effective?
